Pathology News and Research

RSS

Pathology is the study and diagnosis of disease through examination of organs, tissues, bodily fluids, and whole bodies (autopsies). The term also encompasses the related scientific study of disease processes, called General pathology. Medical pathology is divided in two main branches, Anatomical pathology and Clinical pathology. Veterinary pathology is concerned with animal disease whereas Phytopathology is the study of plant diseases.

Sudden epilepsy death explained

Sudden unexpected death in epilepsy (SUDEP) is a condition that kills about 150 Australians a year. Now researchers have discovered the reasons behind such deaths. The study was conducted by scientists at the Centenary Institute at the University of Sydney who looked at blood samples taken from epilepsy suffers who had died suddenly and found that there were genetic faults in the heart and brain.

7 Nov 2010

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

Nanotherapeutics, Inc. announced that it has been awarded a contract by the U.S. Department of Defense to support a clinical trial for treating dehisced surgical wounds with the Company's NanoDOX Hydrogel, a topical doxycycline hydrogel for chronic wounds.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

NinePoint Medical awarded $250,000 grant from Qualifying Therapeutic Discovery Project Program

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has been awarded a grant of approximately $250,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The QTDP's grants and tax credits are provided under the new section 48D of the Internal Revenue Code (IRC), enacted as part of the Patient Protection and Affordable Care Act of 2010.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

New technique could help scientists to predict how living prostate tissues respond to therapy

Scientists at the Johns Hopkins Kimmel Cancer Center, University of Helsinki and Stanford University have developed a technique to keep normal and cancerous prostate tissue removed during surgery alive and functioning normally in the laboratory for up to a week.

3 Nov 2010

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Study finds DHA supplementation does not reduce risk of AD

Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.

3 Nov 2010

Mouse study indicates black raspberries can prevent colorectal cancer

Black raspberries are highly effective in preventing colorectal tumors in two mouse models of the disease, according to a University of Illinois at Chicago study. The findings are published in the November issue of Cancer Prevention Research.

3 Nov 2010

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has been notified that it has been awarded approximately $489,000 total in two federal grants under the Qualifying Therapeutic Discovery Project ("QTDP") Program.

2 Nov 2010

Cascade enters non-binding letter of intent to acquire AcuNetx

Cascade Technologies Corp. announced today that it has entered into a non-binding letter of intent to acquire all of the assets of AcuNetx, Inc., a Nevada corporation in exchange for common stock of Cascade.

2 Nov 2010

Dr Sartori’s contentious alternative therapy: inquest date set

The Medical Practitioner's Board of Western Australia is looking into the case of a doctor and her role in an alternative cancer therapy program. Five cancer patients have died after apparently being given industrial solvents and dangerous minerals as a part of an alternative therapy program by Alexandra Boyd, a well-known Mosman Park breast cancer specialist. She along with two registered nurses administered the concoctions to the people in question.

1 Nov 2010

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

An overwhelming majority of Breast Cancer Surveillance Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) in the U.S. are up-to-par with American College of Radiology Imaging Network (ACRIN) and European Society of Breast Imaging (EUSOBI) technical standards and requirements, according to a study in the November issue of the Journal of the American College of Radiology.

1 Nov 2010

National Conference to educate breast cancer patients about personal health

Leading breast cancer experts and survivors will present at this weekend's Body, Mind, Spirit 2010: National Conference for Young Women Living with Breast Cancer. Presented by the Canadian Breast Cancer Network and co-presenter the Canadian Breast Cancer Foundation, this conference hosts young women with breast cancer to educate them in all aspects of their cancer journey.

30 Oct 2010

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

Pharmaceutical Strategic Initiatives announced today that some of the leading experts in the field of thrombosis and anticoagulation provided their perspective and assessment of new clinical challenges at a recent symposium held at the XXXIII World Congress of the International Society of Hematology held in Jerusalem, Israel on October 12, 2010.

30 Oct 2010

MGH Institute shatters fundraising records at Annual Scholarship Gala

MGH Institute of Health Professions shattered fundraising records at its 4th Annual Scholarship Gala, raising $425,000 at the October 28, 2010 event.

30 Oct 2010

Study suggests curcumin may be an effective therapy for liver fibrosis

Curcumin, a chemical that gives curry its zing, holds promise in preventing or treating liver damage from an advanced form of a condition known as fatty liver disease, new Saint Louis University research suggests.

30 Oct 2010

Research on Rictor protein may provide new molecular target for cancer treatment

The discovery that a protein called Rictor plays a key role in destroying a close cousin of the AKT oncogene could provide scientists with a new molecular target for treating certain cancers, including breast cancer. Described in the September 2010 issue of the journal Molecular Cell, the study was led by scientists at Beth Israel Deaconess Medical Center (BIDMC).

29 Oct 2010

Pathology News and Research

Further Reading

Sudden epilepsy death explained

Nanotherapeutics receives contract from DOD to support clinical trial for treating dehisced surgical wounds

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

Gene fusion prostate cancers susceptible to secondary mutations

NinePoint Medical awarded $250,000 grant from Qualifying Therapeutic Discovery Project Program

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

New technique could help scientists to predict how living prostate tissues respond to therapy

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Study finds DHA supplementation does not reduce risk of AD

Mouse study indicates black raspberries can prevent colorectal cancer

Pro-Pharmaceuticals awarded $489,000 in federal grants under Qualifying Therapeutic Discovery Project

Cascade enters non-binding letter of intent to acquire AcuNetx

Dr Sartori’s contentious alternative therapy: inquest date set

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

National Conference to educate breast cancer patients about personal health

Experts at XXXIII World Congress present new clinical challenges about thrombotic disorders

MGH Institute shatters fundraising records at Annual Scholarship Gala

Study suggests curcumin may be an effective therapy for liver fibrosis

Research on Rictor protein may provide new molecular target for cancer treatment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News